Prevention and Reversal of Type 1 Diabetes—Past Challenges and Future Opportunities
Author:
- 12 May 2015
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 38 (6) , 997-1007
Abstract
Over the past three decades there have been a number of clinical trials directed at interdicting the type 1 diabetes (T1D) disease process in an attempt to prevent the development of the disease in those at increased risk or to stabilize—potentially even reverse—the disease in people with T1D, usually of recent onset. Unfortunately, to date there has been no prevention trial that has resulted in delay or prevention of T1D. And, trials in people with T1D have had mixed results with some showing promise with at least transient improvement in β-cell function compared with randomized control groups, while others have failed to slow the decline in β-cell function when compared with placebo. This Perspective will assess the past and present challenges in this effort and provide an outline for potential future opportunities.Keywords
This publication has 81 references indexed in Scilit:
- Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 DiabetesPLOS ONE, 2012
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trialThe Lancet, 2011
- Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trialThe Lancet, 2011
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- Residual Beta Cell Function in Newly Diagnosed Type 1 Diabetes after Treatment with Atorvastatin: The Randomized DIATOR TrialPLOS ONE, 2011
- Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in ManDiabetes, 2011
- Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 DiabetesDiabetes Care, 2010
- C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes MellitusJAMA, 2009
- Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety studyClinical and Experimental Immunology, 2008
- GAD Treatment and Insulin Secretion in Recent-Onset Type 1 DiabetesNew England Journal of Medicine, 2008